There has been significant investment in developing novel therapies to target solid tumour vasculature. Different technical approaches have been utilized with the aim of inhibiting tumour angiogenesis or compromising the function or stability of pre-existing tumour blood vessels. The vascular endothelial growth factor (VEGF) signalling axis remains the most widely studied, with biological and small-molecule therapeutics now registered for clinical use. However, despite these successes, the activity of these agents is not as widespread as was first postulated. The present review discusses the clinical successes of the VEGF inhibitors, the factors that may limit their utility, and the potential opportunities to maximize benefit from treatment with these agents in the future.
Skip Nav Destination
Article navigation
December 2014
-
Cover Image
Cover Image
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
Conference Article|
November 17 2014
Mechanisms that influence tumour response to VEGF-pathway inhibitors
Neil R. Smith;
Neil R. Smith
1
*Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.
Search for other works by this author on:
Stephen R. Wedge;
Stephen R. Wedge
1
†Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne NE2 4HH, U.K.
Search for other works by this author on:
Aurelien Pommier;
*Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.
Search for other works by this author on:
Simon T. Barry
*Oncology Innovative Medicines, AstraZeneca, Alderley Park, Macclesfield, Cheshire SK10 4TG, U.K.
3To whom correspondence should be addressed (emailSimon.T.Barry@astrazeneca.com).
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 23 2014
Online ISSN: 1470-8752
Print ISSN: 0300-5127
© The Authors Journal compilation © 2014 Biochemical Society
2014
Biochem Soc Trans (2014) 42 (6): 1601–1607.
Article history
Received:
September 23 2014
Citation
Neil R. Smith, Stephen R. Wedge, Aurelien Pommier, Simon T. Barry; Mechanisms that influence tumour response to VEGF-pathway inhibitors. Biochem Soc Trans 1 December 2014; 42 (6): 1601–1607. doi: https://doi.org/10.1042/BST20140261
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Captcha Validation Error. Please try again.